These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31551193)

  • 21. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
    Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
    J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
    Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J
    Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.
    White WB; Dobs A; Carson C; DelConte A; Khera M; Miner M; Shahid M; Kim K; Chidambaram N
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):630-637. PubMed ID: 34191621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compounded percutaneous testosterone gel: use and effects in hypogonadal men.
    Cutter CB
    J Am Board Fam Pract; 2001; 14(1):22-32. PubMed ID: 11206690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
    Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG
    J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
    Dobs AS; Hoover DR; Chen MC; Allen R
    J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
    Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
    Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Xyosted--a testosterone auto-injector for hypogonadism.
    Med Lett Drugs Ther; 2019 Mar; 61(1567):37-38. PubMed ID: 30845097
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.